新型冠状病毒（SARS-CoV-2）传染性强，病死率高，目前无有效的治疗方法。病毒主要侵袭患者的肺部，重症患者多因合并急性呼吸窘迫综合征、脓毒症休克等导致多器官功能衰竭。新型冠状病毒肺炎（COVID-19）的进展程度与患者的免疫状态密切相关，乌司他丁可以有效抑制炎性因子的释放及改善免疫状况，临床应用可降低急性呼吸窘迫综合征及脓毒症患者的死亡率，而且该药还可以和激素或血必净联合使用，进一步增强临床疗效，且无明显的不良反应。因此认为乌司他丁用于减轻COVID-19重症患者的肺损伤有一定的可行性。

New coronavirus (SARS-CoV-2) is highly contagious and has a high fatality rate, and there is no definitive and effective treatment at present. The virus mainly invades the lungs, COVID-19 severe patients have ARDS or septic shock will lead to multiple organ failure. The progression of the new coronavirus pneumonia is closely related to the immune state of patients. Ulinastatin can effectively inhibit the release of inflammatory factors and improve immune status. So we use it to reduce the mortality rate of ARDS and sepsis patients in clinical application. Moreover, Ulinastatin can be used in combination with hormone or Xuebijing to further enhance the clinical efficacy without obvious adverse reactions. So Ulinastatin can be used to reduce the injury in severe COVID-19 patients.

R978.7